Vertex Pharmaceuticals Hits Record Stock High After $10 Billion Acquisition

Vertex Pharmaceuticals reached an all-time high stock price driven by a 12 percent year-over-year increase in second-quarter sales, which totaled $3.33 billion. Revenue from the company's core cystic fibrosis business accounted for $3.2 billion of that total.

To diversify its portfolio and mitigate risks from future competition, the company acquired Crinetics Pharmaceuticals in a $10 billion cash deal to gain access to hormonal disease treatments such as Palsonify. This strategic expansion follows clinical trial failures by competitors, including AbbVie and Sionna Therapeutics, the latter of which saw its leading cystic fibrosis candidate fail a mid-stage study.

Vertex is further expanding its pipeline by seeking U.S. regulatory approval for povetacicept, a treatment for IgA nephropathy, by late November. Additionally, the company expanded the label for its gene-editing medicine, Casgevy, to include children as young as two years old.